
-
Recursion Pharmaceuticals NasdaqGS:RXRX Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Location: 41 South Rio Grande Street, Salt Lake City, UT, 84101, United States | Website: https://www.recursion.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
1.403B
Cash
500.5M
Avg Qtr Burn
-97.21M
Short % of Float
26.82%
Insider Ownership
5.07%
Institutional Own.
75.94%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
REC-4881 Details Familial Adenomatous Polyposis | Phase 2 Data readout | |
REC-4881 Details Cancer | Phase 2 Data readout | |
REC-3964 Details Clostridium difficile Colitis | Phase 2 Update | |
REC-1245 Details Cancer | Phase 1/2 Data readout | |
REC-4539 Details Small cell lung cancer, Cancer | Phase 1/2 Initiation | |
REC-3565 Details R/R B-cell Lymphoma | Phase 1 Data readout | |
REC-617 Details Solid tumor/s, Cancer | Phase 1 Update | |
REV102 Details Hypophosphatasia (HPP) | Phase 1 Initiation | |
REC-2282 Details Neurofibromatosis Type 2-mutated meningiomas | Failed Discontinued | |
REC-3599 Details GM2 gangliosidosis | Failed Discontinued | |
REC-994 Details Cerebral cavernous malformation | Failed Discontinued |